Novartis turns to BeiGene again for the next big checkpoint target, paying $300M to jump into TIGIT race

Count Novartis in for the burgeoning TIGIT race.

After starting the year by plunking down $650 million upfront to license BeiGene’s PD-1 inhibitor …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis turns to BeiGene again for the next big check­point tar­get, pay­ing $300M to jump in­to TIG­IT race